Arcturus Therapeutics Holdings (ARCT) Other Non-Current Assets (2018 - 2026)
Arcturus Therapeutics Holdings' (ARCT) quarterly Other Non-Current Assets came in at $2.0 million in Q1 2026, down 88.97% YoY from $18.4 million in Q1 2025, and up 7.59% on a QoQ basis from $1.9 million in Q4 2025.
Analysis
Arcturus Therapeutics Holdings (ARCT) Other Non-Current Assets (2018 - 2026) Analysis & Trends
Arcturus Therapeutics Holdings (ARCT) has 9 years of Other Non-Current Assets data on file, last reported at $2.0 million in Q1 2026.
- Quarterly Other Non-Current Assets fell 88.97% year-over-year to $2.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.0 million (down 88.97% YoY) and the FY2025 annual result came in at $1.9 million, changed 0.0% from the prior year.
- Other Non-Current Assets climbed to $2.0 million in Q1 2026, from $1.9 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $22.1 million in Q3 2023 to a low of $1.9 million in Q4 2023.
- A 5-year average of $4.1 million and a median of $2.0 million in 2026 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets soared 1842.06% — and 2024, when it slumped 91.48%.
- Tracing ARCT's Other Non-Current Assets over 5 years: stood at $2.1 million in 2022, then declined by 9.98% to $1.9 million in 2023, then changed by 0.0% to $1.9 million in 2024, then changed by 0.0% to $1.9 million in 2025, then rose by 7.59% to $2.0 million in 2026.
- The last three Other Non-Current Assets figures came in at $2.0 million (Q1 2026), $1.9 million (Q4 2025), and $1.9 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 618.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 42.45 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 109.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 65.13 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 62.96 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Arcturus Therapeutics Holdings | 449.65 Mn | 258.17 Mn | - | 2.03 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.03 Mn |
| Mar 31, 2026 | 2.03 Mn |
| Dec 31, 2025 | 1.89 Mn |
| Sep 30, 2025 | 1.89 Mn |
| Jun 30, 2025 | 1.89 Mn |
| Mar 31, 2025 | 18.39 Mn |
| Dec 31, 2024 | 1.89 Mn |
| Sep 30, 2024 | 1.89 Mn |
| Jun 30, 2024 | 1.89 Mn |
| Mar 31, 2024 | 1.89 Mn |
| Dec 31, 2023 | 1.89 Mn |
| Sep 30, 2023 | 22.13 Mn |
| Jun 30, 2023 | 2.13 Mn |
| Mar 31, 2023 | 2.12 Mn |
| Dec 31, 2022 | 2.09 Mn |
| Sep 30, 2022 | 2.08 Mn |
| Jun 30, 2022 | 2.08 Mn |
| Mar 31, 2022 | 2.08 Mn |
| Dec 31, 2021 | 2.08 Mn |
| Sep 30, 2021 | 2.07 Mn |